Rethinking Resident Perceptions of Tourism in British Columbia, Canada

This joint academic/practitioner report segments British Columbia, Canada residents to provide destination managers with new ways to better understand resident perceptions of tourism. The data collection was conducted in April and May of 2022 and had a total of 2,265 valid responses. It was also a practical objective to conduct this research in a manner that is repeatable in jurisdictions beyond British Columbia. This report has confirmed five distinct categories of residents’ perceptions toward tourism, including socio-cultural, economic, environmental, job/career, and Indigenous impacts. In addition to the categories of impacts, a cluster analysis has revealed six clusters of residents based on the five categories: Tourism Ambassadors, Tourism Supporters, Socio-cultural and Tourism Economic Supporters, Neutrals, Concerns about Careers and Environment, and Tourism Adversaries. Managerial implications and opportunities for future destination management and governance are discussed

Exercising in the Fasted State Reduced 24-Hour Energy Intake in Active Male Adults

The effect of fasting prior to morning exercise on 24-hour energy intake was examined using a randomized, counterbalanced design. Participants (12 active, white males, 20.8±3.0 years old, VO2max:   59.1±5.7 mL/kg/min) fasted (NoBK) or received breakfast (BK) and then ran for 60 minutes at 60%  VO2max. All food was weighed and measured for 24 hours. Measures of blood glucose and hunger were collected at 5 time points. Respiratory quotient (RQ) was measured during exercise. Generalized linear mixed models and paired sample t-tests examined differences between the conditions. Total 24-hour (BK: 19172±4542 kJ versus NoBK: 15312±4513 kJ; p<0.001) and evening (BK: 12265±4278 kJ versus NoBK: 10833±4065; p=0.039) energy intake and RQ (BK: 0.90±0.03 versus NoBK: 0.86±0.03; p<0.001) were significantly higher in BK than NoBK. Blood glucose was significantly higher in BK than NoBK before exercise (5.2±0.7 versus 4.5±0.6 mmol/L; p=0.025). Hunger was significantly lower for BK than NoBK before exercise, after exercise, and before lunch. Blood glucose and hunger were not associated with energy intake. Fasting before morning exercise decreased 24-hour energy intake and increased fat oxidation during exercise. Completing exercise in the morning in the fasted state may have implications for weight management

A Time Purified Separated Antiproton Beam At The AGS

Physic

First Observation of the Rare Decay Mode K-long -> e+ e-

In an experiment designed to search for and study very rare two-body decay modes of the K-long, we have observed four examples of the decay K-long -> e+ e-, where the expected background is 0.17+-0.10 events. This observation translates into a branching fraction of 8.7^{+5.7}_{-4.1} X 10^{-12}, consistent with recent theoretical predictions. This result represents by far the smallest branching fraction yet measured in particle physics.Comment: 9 pages, 3 figure

Nucleon-nucleon elastic scattering analysis to 2.5 GeV

A partial-wave analysis of NN elastic scattering data has been completed. This analysis covers an expanded energy range, from threshold to a laboratory kinetic energy of 2.5 GeV, in order to include recent elastic pp scattering data from the EDDA collaboration. The results of both single-energy and energy-dependent analyses are described.Comment: 23 pages of text. Postscript files for the figures are available from ftp://clsaid.phys.vt.edu/pub/said/n

Superconducting Fluctuations and the Pseudogap in the Slightly-overdoped High-Tc Superconductor TlSr2CaCu2O6.8: High Magnetic Field NMR Studies

From measurements of the ^{63}Cu Knight shift (K) and the nuclear spin-lattice relaxation rate (1/T_{1}) under magnetic fields from zero up to 28 T in the slightly overdoped superconductor TlSr_{2}CaCu_{2}O_{6.8} (T_{c}=68 K), we find that the pseudogap behavior, {\em i.e.}, the reductions of 1/T_{1}T and K above T_{c} from the values expected from the normal state at high T, is strongly field dependent and follows a scaling relation. We show that this scaling is consistent with the effects of the Cooper pair density fluctuations. The present finding contrasts sharply with the pseudogap property reported previously in the underdoped regime where no field effect was seen up to 23.2 T. The implications are discussed.Comment: 10 pages, 4 GIF figures, to be published in Phys. Rev. Let

On the close to threshold meson production in neutron-neutron collisions

A method of measuring the close to threshold meson production in neutron-neutron collisions is described where the momenta of the colliding neutrons can be determined with the accuracy obtainable for the proton-proton reaction. The technique is based on the double quasi-free nn --> nn X^0 reaction, where deuterons are used as a source of neutronsComment: 6 pages, 2 figures, to be published in Phys. Lett.

Vortex State of Tl2_2Ba2_2CuO6+δ_{6+\delta} via 205^{205}Tl NMR at 2 Tesla

We report a $^{205}$Tl NMR study of vortex state for an aligned polycrystalline sample of an overdoped high-$T_c$ superconductor Tl$_2$Ba$_2$CuO$_{6+\delta}$ ($T_{c}\sim$85 K) with magnetic field 2 T along the c axis. We observed an imperfect vortex lattice, so-called Bragg glass at $T$=5 K, coexistence of vortex solid with liquid between 10 and 60 K, and vortex melting between 65 and 85 K. No evidence for local antiferromagnetic ordering at vortex cores was found for our sample.Comment: 4 pages with 5 figure

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility. Methods A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1wt or ESR1Y537S, modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies. Results Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops associated with RAD001. Conclusions Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER